The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IP License Agreements

25 Jun 2009 07:00

RNS Number : 4577U
Amphion Innovations PLC
25 June 2009
 



Amphion Innovations plc Partner Company, DataTern,  Signs Four License Agreements worth $1.8 million

 

London and New York, 25 June 2009 - Amphion Innovations plc (LSE: AMP) ("Amphion"), the developer of medical and technology businesses, today announces that its wholly owned subsidiary DataTern, Inc., has signed additional non-exclusive intellectual property license agreements with four leading international corporations for a total of $1.8 million. DataTern has signed eleven licenses since it commenced licensing of this product in June 2008, generating total revenues of approximately $8.8 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, airline, e-commerce, and software industries.

 

DataTern, Inc., was established in order to commercialise selected intellectual property opportunities in partnership with Amphion's Partner Companies. 

 

Joseph Flicek, DataTern's Chief Executive Officer, said: 

"We are pleased to announce these four additional license agreements, which we believe reflect the strength and breadth of DataTern's technologies. We are currently in discussions with over 15 additional organisations about licensing our products and look forward to announcing further licensees in the second half of the year." 

Richard Morgan, Chief Executive Officer of Amphion, said: 

"We were pleased to see DataTern's intellectual property licensing programme get back on track in May and with these four new license agreements we have surpassed our plan for the first half year. Amphion's eight Partner Companies are all built on innovative and important intellectual property foundations and between them they own or control over 200 separately identified pieces of intellectual property. This represents a rich reservoir of opportunity to replicate the success of our first programme and build on the expertise we have developed in this field."

 

For further information please contact

Amphion Innovations Charlie Morgan +1 (212) 210-6224

Cardew GroupTim Robertson/ Jamie Milton/ Matthew Law +44 20 7930 0777

Charles Stanley (Nominated Adviser) Mark Taylor/ Freddy Crossley +44 207149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 10 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

 

About DataTern, Inc.

DataTern owns and develops critical technology that provides next generation software solutions for its customers. DataTern's patented product offerings include ObjectSpark® Technologies, which allow customers to develop their own customised data service layers, making the company's offerings valuable to most industries, including automotive, banking, chemical, communications, financial, government, healthcare, insurance, pharmaceutical, trading, and many others. Non-exclusive licenses for DataTern's technologies and patents are available on reasonable and non-discriminatory terms. 

For licensing terms, please contact info@datatern.com

On the web: www.datatern.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRFIMATMMITBRL
Date   Source Headline
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.